HYPR Posts Revenue Surge, But Loss Narrows Just 43%

Hyperfine (HYPR) reported mixed Q4 2025 results, with revenue exceeding $5 million (128% YoY growth) but GAAP EPS of -$0.06 beating estimates by $0.02. The company narrowed its net loss by 43.1% to $5.91 million and provided 2026 guidance of $20–22 million in revenue, reflecting 55% YoY growth at the midpoint.

Revenue

Hyperfine’s total revenue surged to $5.29 million in Q4 2025, a 128.0% increase from $2.32 million in Q4 2024. This growth was driven by strong adoption of the Swoop MRI system, particularly in hospitals and international markets.

Earnings/Net Income

The company narrowed its per-share loss to $0.06 from $0.14, a 57.2% improvement, while reducing its net loss to $5.91 million (down 43.1% YoY). Despite progress, Hyperfine has sustained losses for five consecutive years, underscoring ongoing financial challenges. The EPS improvement, though positive, remains a loss.

Price Action

Hyperfine’s stock declined 3.05% on the latest trading day but gained 7.63% weekly and 14.41% month-to-date, reflecting mixed short-term investor sentiment.

Post-Earnings Price Action Review

The strategy of purchasing Hyperfine shares following revenue declines in Q4 reports has historically underperformed, delivering a -71.11% return over three years. This approach lagged the benchmark by 119.67%, with a Sharpe ratio of -0.26 and a maximum drawdown of 88.33%, highlighting its risk profile.

CEO Commentary

CEO Maria Sainz emphasized the Swoop system’s role in driving revenue, citing its ultra-low field MRI technology and expanding use cases like stroke detection. Strategic priorities include AI software development, international expansion (e.g., India), and achieving 1–1.5-year ROI for hospitals.

Guidance

Hyperfine projects 2026 revenue of $20–22 million, with gross margins of 50–55%, driven by multi-unit hospital deals and international growth. Cash burn is expected to decline 10% to $26–28 million, reflecting disciplined spending and debt management.

Additional News

Hyperfine’s international expansion is progressing steadily, with a focus on India and mobile dementia screening. The company also advanced its AI-driven Optive software, recently cleared by the FDA. While cash burn remains a challenge, management noted improved pricing strategies and a diversified pipeline of hospital and IDN deals.